Searched for
NATCO COVID TREATMENT
Natco Pharma signs pact with MPP to sell Molnupiravir capsulesNatco Pharma has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupi...- Mankind Pharma set to roll out cheapest coronavirus drugThe full treatment of Molulife (brand name) is expected to cost ₹1,400, RC Juneja, chairman of Mankind Pharma, told ET. The brand is expect...
- Pharma stocks gain as DGCI approves emergency use of COVID pill MolnupiravirShares of Strides Pharma were up 2.3 per cent while those of Cipla gained 1.4 per cent. Dr Reddy’s scrip registered a gain of close to a pe...
- Natco Pharma plans to launch Molnupiravir capsules this week for treatment of COVID-19Molnupiravir is the first COVID-19 drug authorised by the Drugs Controller General of India (DCGI) for the treatment of COVID-19 infection ...
- SEC to review companies' applications for Molnupiravir on MondayThe drug is touted as a game-changer in the fight against the pandemic, and a panel of experts of the US Food and Drug Administration (FDA)...
- Natco Pharma, Hetero seek marketing authorisation for anti-Covid drug molnupiravirNatco has conducted Phase III trials of molnupiravir and submitted the trial results to the drug regulator this month. "We have submitted p...
- Natco Pharma shares hit upper circuit. Here's whyThe Hyderabad-based firm said the first dose under the phase-III trials was given to a patient in the city-based Yashoda Hospitals.
- Natco initiates phase-3 clinical trials of Molnupiravir capsules for COVID-19 treatmentNatco Pharma on Friday said it has initiated phase-III clinical trials of Molnupiravir capsules to evaluate its efficacy in treating patien...
- Yashoda Hospitals joins Natco for clinical trials of Molnupiravir for Covid patientsPre-clinical (animal) studies have found that Molnupiravir has remarkably reduced SARS-CoV-2 load and was found to have completely suppress...
- Eli Lilly buckles under pressure, offers voluntary licence to Natco PharmaLily has issued voluntary licenses for Barcitinib to six Indian drug makers besides Natco, these include- Sun Pharma, Cipla, Dr Reddy's, Lu...
- Eli Lilly inks pacts for Baricitinib with Sun Pharma, Cipla, Lupin for COVID-19 treatment in IndiaAs the threat of compulsory licence (CL) looms over big pharma in India, companies are rushing in to sign voluntary licensing agreements th...
- Covid drug: Natco eyes patent waiverIn its application, Natco has cited the unmet medical needs due to the lack of supply and affordability in light of the grave and life-thre...
- Roche India gets emergency use approval for antibody cocktail used in COVID-19 treatmentRoche said that the production process for this drug is “very complex” and the company will do everything to ensure an equitable distributi...
- Covid drug: Natco eyes patent waiverMaking its case, Natco’s application said Olumiant is not manufactured in India — less than 9,000 tablets were imported in 2019 and 2020, a...
- Natco gets emergency use nod for Baricitinib to treat Covid without trialsIn a statement, the Hyderabad headquartered pharma company said Baricitinib in combination with Remdesivir is used for the treatment of Cov...
- Natco Seeks emergency approval to launch Molnupiravir for Covid-19 in IndiaMolnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...
- Natco seeks emergency nod for Molnupiravir to treat CovidThe development comes close on the heels of findings announced by the researchers that Molnupiravir was found effective for treating the pa...
- Natco Pharma's comparatively reasonable valuation makes it stock pick of the weekNatco’s recent diversification of its exports to markets like Brazil, Canada, China, is doing well and is expected to do so in future as we...
- SEC denies emergency nod to Natco Covid-19 drugNatco had in December sought a waiver of the clinical trial requirement for the emergency use of baricitinib tablets in Covid-19 treatment,...
- Hyderabad-based Natco Pharma wants to make Eli Lilly’s Covid drugNatco has sought nod for the manufacture and marketing of baricitinib bulk drug and tablets in 1 to 4 mg versions in India. This move may t...
Load More
